针药结合治疗血瘀下焦型良性前列腺增生的临床观察
|
摘要
目的：观察针刺结合川参通注射液治疗血瘀下焦型良性前列腺增生的临床疗效。
方法：选择确诊为良性前列腺增生并符合纳入标准的60例患者,采用随机表法将其随机分入治疗组(针刺+川参通注射液)和对照组(针刺),每组各30例。治疗28天,观察良性前列腺增生患者治疗前后国际前列腺症状评分、生活质量评分、中医症状评分、最大尿流率、残余尿量、前列腺体积的变化。
结果：1、治疗组疗效优于对照组(P<0.05)。2、两组患者的国际前列腺症状评分、生活质量评分、中医症状评分和残余尿量治疗后均比治疗前减少,而最大尿流率治疗后均比治疗前增加；且治疗组上述指标的改善程度优于对照组(P<0.05)。3、治疗后两组患者的前列腺体积均未缩小(P>0.05)。
结论：针刺结合川参通注射液治疗血瘀下焦型良性前列腺增生,能改善患者的国际前列腺症状评分、生活质量评分、中医症状评分、最大尿流率、残余尿量,在改善症状和提高患者生活质量方面与针刺比较有一定的优势。
Objective:TO evaluate the clinical efficacy of Acupuncture combined with Chuan ShenTong injection in the treatment of blood stasis and lower warmer type Benign Prostatic Hyperplasia(BPH).
Methods:Select diagnosed benign prostatic hyperplasia met the inclusion criteria of the 60 patients, using random table method, and randomly divided into treatment group (Acupuncture +Chuanshentong injection) and control group (Acupuncture),30 patients in each group. Therapy 28 days, observed in patients with benign prostatic hyperplasia before and after treatment the International Prostate Symptom Score, quality of life score, clinical symptoms score, maximum flow rate, residual urine volume, prostate volume changes.
Result:1.The curative effect of treatment group was better than control group (P<0.05). 2.two groups of international prostate symptom score, quality of life scores, symptom scores of Chinese medicine and residual urine volume after treatment than before treatment decreased, while the maximum flow rate increased after treatment than before treatment; and the improvement of the treatment group, these indicators Degree than the control group(P<0.05).3.After treatment, the two sets of patients prostate volume were not shrink (P>0.05).
Conclusion:Acupuncture combined with Chuanshentong injection in treatment of Blood stasis under and Lower Warmer type of benign prostatic hyperplasia model can improve the international prostate symptom score of patients, quality of life score, clinical symptoms score, maximum flow rate, residual urine volume, in improving symptoms and improve the lives of patients Quality and Acupuncture participation in general has certain advantages injection comparison.
方法：选择确诊为良性前列腺增生并符合纳入标准的60例患者,采用随机表法将其随机分入治疗组(针刺+川参通注射液)和对照组(针刺),每组各30例。治疗28天,观察良性前列腺增生患者治疗前后国际前列腺症状评分、生活质量评分、中医症状评分、最大尿流率、残余尿量、前列腺体积的变化。
结果：1、治疗组疗效优于对照组(P<0.05)。2、两组患者的国际前列腺症状评分、生活质量评分、中医症状评分和残余尿量治疗后均比治疗前减少,而最大尿流率治疗后均比治疗前增加；且治疗组上述指标的改善程度优于对照组(P<0.05)。3、治疗后两组患者的前列腺体积均未缩小(P>0.05)。
结论：针刺结合川参通注射液治疗血瘀下焦型良性前列腺增生,能改善患者的国际前列腺症状评分、生活质量评分、中医症状评分、最大尿流率、残余尿量,在改善症状和提高患者生活质量方面与针刺比较有一定的优势。
Objective:TO evaluate the clinical efficacy of Acupuncture combined with Chuan ShenTong injection in the treatment of blood stasis and lower warmer type Benign Prostatic Hyperplasia(BPH).
Methods:Select diagnosed benign prostatic hyperplasia met the inclusion criteria of the 60 patients, using random table method, and randomly divided into treatment group (Acupuncture +Chuanshentong injection) and control group (Acupuncture),30 patients in each group. Therapy 28 days, observed in patients with benign prostatic hyperplasia before and after treatment the International Prostate Symptom Score, quality of life score, clinical symptoms score, maximum flow rate, residual urine volume, prostate volume changes.
Result:1.The curative effect of treatment group was better than control group (P<0.05). 2.two groups of international prostate symptom score, quality of life scores, symptom scores of Chinese medicine and residual urine volume after treatment than before treatment decreased, while the maximum flow rate increased after treatment than before treatment; and the improvement of the treatment group, these indicators Degree than the control group(P<0.05).3.After treatment, the two sets of patients prostate volume were not shrink (P>0.05).
Conclusion:Acupuncture combined with Chuanshentong injection in treatment of Blood stasis under and Lower Warmer type of benign prostatic hyperplasia model can improve the international prostate symptom score of patients, quality of life score, clinical symptoms score, maximum flow rate, residual urine volume, in improving symptoms and improve the lives of patients Quality and Acupuncture participation in general has certain advantages injection comparison.
引文
1张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：97.
2 Rowhrborm CG, McConnell JD. Etiology, pathothysiology, epidemiology and natural history of benign prostatic hyperplasia. In:Campbell's Urology. Edited by PC Walsh, AB Retik, ED Vaughan Jr and AJ Wein Philadelphia, PA:W.B. Saunders Company,2002,38:1297-1330.
3顾方六.良性前列腺增生的药物治疗.现代前列腺病学[M].北京：人民军医出版社,2001：158.
4 BahkJY, Hyunjs, LeeJY.Coneentration of loxae in canine Prostate tissue and Prosrate fluid after intraPtos ratic iniecrion of biode gradable sustained releasing microspheres containing of losacin[J]. JUrol,2000,163(5):1560-1564.
5贾金铭,张亚强.川参通注射液治疗前列腺增生症2090例临床疗效观察[J].中药新药与临床药理,2002,13(4)：206.
6颜鸿,安国术.川参通注射液治疗慢性前列腺炎临床疗效观察(附342例治疗报告)[J].临床医药实践杂志,2008,17(9)：743-744.
7张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：105-106.
8国家中医药管理局.中医病症诊断疗效标准[M].南京：南京大学出版社,1994：49.
9郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：384-385.
10张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：107.
11 Schafer, Abrams P, Liao LM, et al.Good urodynamic practices:uroflowmetry, filling cystometry, and pressure-flow studies.Neurourol Urodyna,2002,21.
12王健,齐晓涟,张乃文.近期良性前列腺增生药物治疗及不良反应进展[J].中国全科医学,2004,7(11)：823.
13 Sciarra F, Toscano V.Role of estrogens in human benign prostatic hyperplasia.ArchAndrol, 2000,44(3),213-220.
14 Van-Coppenolle F, Slomianny C, Carpentier F, et al.Effects of hyperpro lactinemia on rat prostate of androgeno-dependence Am J Physiol Endocrinol,2001,280(1),120-29.
15张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：98.
16内经.素问.宣明五气篇[M].北京：科学技术出版社,1996：43.
17曾庆佩.复方术归丸治疗前列腺增生症21例[J].浙江中医杂志,1994,29(1)：12.
18张关荣.从瘀辨治前列腺增生52例[J].四川中医,1997,15(10)：27.
19常仁,汪觉生,袁鸿江,等.健康老年人高凝状态的诊断探讨[J].中华老年医学杂志.1993,12(1)：41.
20潘立群.试论前列腺增生症病机的确切含义[J].江苏中医药.2002,23(6)：1-2.
21陈和亮.实用中医男科临床手册[M].上海：上海中医药大学出版社,2006：159.
22郑中炎.中医基础理论体系现代研究[M].广东：广东科技出版社,2002：198.
23何红兵.从瘀辨证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3)：181.
24徐恒泽.针灸学[M].第1版,北京：人民卫生出版社,2002：84-165.
25安军明,殷克敬,苏同生.针刺对实验性前列腺增生的防治作用[J].中国中西医结合外科杂志,1998,4(6)：363.
26袁庆东,肖向茜,等.电针用于治疗大鼠前列腺增生症实验性机制研究[J].中国康复医学杂志,2008,23(6)：534.
27冀来喜.针刺秩边对实验性非菌性前列腺炎大鼠前列腺微循环的影响[J].中国针灸,2001,21(1)：45-46.
28邓春雷.调整膀胱机能的穴位特异性及其实质的探讨[J].上海针灸杂志,1987(3)：17-19.
29吴定宗,杨立平,邓春雷.针刺对下丘脑后部与延髓排尿中枢及膀胱机能的影响[J].中国针灸,1982,(5)：15.
30郑蕙田,黄羡明,孙吉山,等.针灸对膀胱、尿道的调节作用[J].中国医药学报,1990,5(6)：41.
31石吉娣,傅云其.长毫针深斜刺关元穴治疗86例尿潴留症临床观察[J].针灸临床杂志,1999,15(1)：49-50.
32陶之理,任文庆.“关元俞”、“膀胱俞”传入神经元与膀胱传入神经元的阶段性分布联系一经穴脏腑相关一足太阳膀胱经研究[J].针刺研究,1995,20(4)：17-2.
33李忠任.实验针灸学[M].第1版,北京：中国中医药出版社,2003：229-230.
34敖有光,杨运宽,胡幼平.针灸加穴位注射治疗痔瘘术后尿潴留67例[J].福建中医药,2003,34(6)：33.
35刘红,熊典樟,朱贤苟.针灸治疗182例药源性尿潴留的临床研究[J].中国民康医学杂志, 2003,15(9)：546.
36陈跃来,申鹏飞,陈国美,等.电针“会阳”、“中膂俞”对非细菌性前列腺炎大鼠尿流动力学影响的实验研究[J].针刺研究,2001,26(2)：127-130.
37王建文,赵耀东,雄成林.电针对大鼠前列腺增生的治疗作用及对一氧化氮内皮素的影响[J].中医药学刊,2004,22(11)：2130-2131.
38李锦宇,韩霞,汪晓斌.针灸免疫研究概况[J].动物医学进展,2008,29(11)：107-110.
39赵淑华,吉学群,许洪玲,等.血海穴活血化瘀功能的再评价[J].中国针灸,2004,24(7)：475-478.
40雷正权,殷克敬.针刺活血化瘀穴对血中纤维蛋白原的影响.陕西中医学院学报[J].1994,17(3)：15.
41朱静芬.针刺疗法与活血化瘀述略[J].中国中医药现代远程教育,2008,6(8)：932.
42徐天舒,针刺对老年眩晕症病人血液流变学的影响[J].针刺研究,2000,25(4)：281.
43王绍源,谭勇,黄静.川参通注射液治疗慢性前列腺炎[J].中华现代临床医学杂志,2004,2(7)：968.
44巫少荣,李白成,裘汉璋.当归在心血管系统的作用[J].中医药研究,2001,17(3)：56-58.
45韩联合,陈腾,冯国清.川芎嗪和透明质酸钠对兔心脏术后心包粘连的保护作用及对照研究[J].中国临床药理学与治疗学,2006,11(6)：665-668.
46杜健鹏,陈泽涛.益气活血法改善微循环的实验研究[J].中国实验方剂学杂志,2006,12(9)：31-35.
47刘艳凯,刘圣君,张玉平,等.川芎嗪、当归注射液对急性微循环障碍大鼠血小板功能和器官血流量的影响[J].中国医学物理学杂志,2005(5)：660-662.
48吴洪涛,刘紫庭,等.川参通对大鼠前列腺组织影响的实验研究[J].中国临床康复,2005,9(2)：190.
49邢子龙,许衍慧,解春洁.川参通治疗前列腺203例临床观察[J].现代中西医结合杂志,2005,14(1)：46.
50李文涛,宋荣坡,刘茂林.针药结合对脑缺血大鼠脑水肿防治作用的实验研究[J].陕西中医,2003,24(2)：178-179.
51王军,王玉升,齐小玲,等.针药合用对大鼠局灶性脑缺血预后的影响[J].中国临床康复,2002,6(13)：1914-1915.
52呙登俊,万同,田畯,等.尼莫地平联合电针治疗脑缺血再灌注损伤的机理[J].中国康复理论 与实践,2003,9(3)：141-143.
53刘丽军,杜惠兰,靳亚慈,等.针药结合对乳腺增生大鼠乳腺组织及雌激素受体亚型表达的影响[J].中国针灸,2007,27(4)：279-283.
1 Rowhrborm CG, McConnell JD. Etiology, pathothysiology, epidemiology and natural history of benign prostatic hyperplasia. In:Campbell's Urology. Edited by PC Walsh, AB Retik, ED Vaughan Jr and AJ Wein Philadelphia, PA:W.B. Saunders Company,2002,38:1297-1330.
2张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：146.
3鲍镇美.良性前列腺增生的药物治疗[J].中华泌尿外科杂志,1996,17：387.
4 Claus S,Berges R,Senge T,et al.Cell kinetic in epithelium and stro-ma of benign prostatic hyperplasia.J Utol,1997,158:217-21.
5 Sciarra F,Toscano V.Role of estrogens in human benign prostatic hyper-plasia.ArchAndrol, 2000,44(3),213-220.
6 Carballido,Rodriguez,Rodriguez Vallejo,et al.Benign prostatic hyperpla-sia and evidence based medicine:its approach in clinical practice. Med Clin(Barc),2000,114 Suppl 2,96-104.
7Furuya Y,et al.Endocrinology,1995,136:1898-1906.
8夏术阶,许纯孝,马庆铮等.前列腺阶段性增长的雄激素基础研究[J].中国男科学杂志,1999,13(4)：217-219.
9 Van-Coppenolle F,Slomianny C,Carpentier F,et al.Effects of hyperpro lactinemia on rat prostate growth:evidence of androgeno-dependence Am J Physiol Endocrinol,2001,280(1),120-29.
10 Hammarsten J,Hogstedt B.Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.Eur Urol,2001,39(2),151-158.
11 Mochtar CA,Rahardjo D,Umbas R.Ahigher PSA-density cut-off level inpatientswith intermediate PSA values for the early detection of prostate cancer.Gan To Kagaku Ryoho,2000, 27 Suppl 2,514-522.
12 Habermann Helga,Ray Vera,Habermann Walter,et al.Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol,2002,167(2 Pt 1), 655-660.
13 VictorVM,RochaM,DelaFuenteM.Immunecells:freeradicals and antioxidants in sepsis[J].Int Immunopharmacol,2004,4(3):327-347.
14 Kramer QMarberger M.Could inflammation be a key component in the progression of benign prostatic hyperplasia?[J].Curr Opin Urol,2006,16(1):25-29.
15 Penna G, Mondaini N, Amuchastegui S,et al. Seminal plasma andchemokinesin inflammatio cytokines prostate:interleukin 8 as a predictive biomarker in chronic prostat chronic pelvic pain syndrome and benign prostatic hyperplasia[J]. EurUrol,2007,51(2):524-533.
16 Aggarwal S,Gurney A L.IL-17:prototype member of an emerging cytokine family[J]. Leukocgte Biol,2002,71(1):1-8.
17 Konig J E,Senge T,Allhoff E P,et al.Analysis of the inflammatory network in benign prostate hyperplasia and prostatecancer[J].Prostate,2004,58(2):121-129.
18 Steiner G E,Stix U,Handisurya A,et al.Cytokine expres-cells and impact of lymphocytic infiltration on cytokine mRN A profile in prostatic tissue[J]. Lab Invest,2003,83(8):1131-1146.
19 Miller L J,Fischer K A,Goralnick S J,et al.Interleukin-10 levels in seminal plasma implicationsfor chronicpros tatitis chronicpelvicpainsyndrome[J].JUrol,2002,167(2Ptl): 753-756.
20 Jang T L,Schaefer A J.The role of cytokines in prostatisis[J].WorId J Urol2003,21(2):95-99.
21 Kramer Gero,Marberger Michae.1 Could inflammation be a key component in the progession of benign prostatic hyperplasia [J].CurrOpininUro,2006,16:25-29.
22 SteinerG, StixU, HandisuryaA, eta.l Cytokine expression pat-tern in benign prostatic hyperplasia infiltratingT cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue[J]. Lab Invest,2003,83:1131-1146.
23 KramerG, Mitteregger, MarbergerM. Is benign prostatic hyper-plasia (BPH) an immune inflammatory disease[J].EuropUrol,2007,51:1202-1216.
24陈和亮.实用中医男科临床手册[M].上海：上海中医药大学出版社,2006：159.
25郑中炎.中医基础理论体系现代研究[M].广东：广东科技出版社,2002：198.
26潘立群.试论前列腺增生症病机的确切含义[J].江苏中医药.2002,23(6)：1-2.
27何红兵.从瘀辨证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3)：181.
2 Rowhrborm CG, McConnell JD. Etiology, pathothysiology, epidemiology and natural history of benign prostatic hyperplasia. In:Campbell's Urology. Edited by PC Walsh, AB Retik, ED Vaughan Jr and AJ Wein Philadelphia, PA:W.B. Saunders Company,2002,38:1297-1330.
3顾方六.良性前列腺增生的药物治疗.现代前列腺病学[M].北京：人民军医出版社,2001：158.
4 BahkJY, Hyunjs, LeeJY.Coneentration of loxae in canine Prostate tissue and Prosrate fluid after intraPtos ratic iniecrion of biode gradable sustained releasing microspheres containing of losacin[J]. JUrol,2000,163(5):1560-1564.
5贾金铭,张亚强.川参通注射液治疗前列腺增生症2090例临床疗效观察[J].中药新药与临床药理,2002,13(4)：206.
6颜鸿,安国术.川参通注射液治疗慢性前列腺炎临床疗效观察(附342例治疗报告)[J].临床医药实践杂志,2008,17(9)：743-744.
7张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：105-106.
8国家中医药管理局.中医病症诊断疗效标准[M].南京：南京大学出版社,1994：49.
9郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：384-385.
10张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：107.
11 Schafer, Abrams P, Liao LM, et al.Good urodynamic practices:uroflowmetry, filling cystometry, and pressure-flow studies.Neurourol Urodyna,2002,21.
12王健,齐晓涟,张乃文.近期良性前列腺增生药物治疗及不良反应进展[J].中国全科医学,2004,7(11)：823.
13 Sciarra F, Toscano V.Role of estrogens in human benign prostatic hyperplasia.ArchAndrol, 2000,44(3),213-220.
14 Van-Coppenolle F, Slomianny C, Carpentier F, et al.Effects of hyperpro lactinemia on rat prostate of androgeno-dependence Am J Physiol Endocrinol,2001,280(1),120-29.
15张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：98.
16内经.素问.宣明五气篇[M].北京：科学技术出版社,1996：43.
17曾庆佩.复方术归丸治疗前列腺增生症21例[J].浙江中医杂志,1994,29(1)：12.
18张关荣.从瘀辨治前列腺增生52例[J].四川中医,1997,15(10)：27.
19常仁,汪觉生,袁鸿江,等.健康老年人高凝状态的诊断探讨[J].中华老年医学杂志.1993,12(1)：41.
20潘立群.试论前列腺增生症病机的确切含义[J].江苏中医药.2002,23(6)：1-2.
21陈和亮.实用中医男科临床手册[M].上海：上海中医药大学出版社,2006：159.
22郑中炎.中医基础理论体系现代研究[M].广东：广东科技出版社,2002：198.
23何红兵.从瘀辨证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3)：181.
24徐恒泽.针灸学[M].第1版,北京：人民卫生出版社,2002：84-165.
25安军明,殷克敬,苏同生.针刺对实验性前列腺增生的防治作用[J].中国中西医结合外科杂志,1998,4(6)：363.
26袁庆东,肖向茜,等.电针用于治疗大鼠前列腺增生症实验性机制研究[J].中国康复医学杂志,2008,23(6)：534.
27冀来喜.针刺秩边对实验性非菌性前列腺炎大鼠前列腺微循环的影响[J].中国针灸,2001,21(1)：45-46.
28邓春雷.调整膀胱机能的穴位特异性及其实质的探讨[J].上海针灸杂志,1987(3)：17-19.
29吴定宗,杨立平,邓春雷.针刺对下丘脑后部与延髓排尿中枢及膀胱机能的影响[J].中国针灸,1982,(5)：15.
30郑蕙田,黄羡明,孙吉山,等.针灸对膀胱、尿道的调节作用[J].中国医药学报,1990,5(6)：41.
31石吉娣,傅云其.长毫针深斜刺关元穴治疗86例尿潴留症临床观察[J].针灸临床杂志,1999,15(1)：49-50.
32陶之理,任文庆.“关元俞”、“膀胱俞”传入神经元与膀胱传入神经元的阶段性分布联系一经穴脏腑相关一足太阳膀胱经研究[J].针刺研究,1995,20(4)：17-2.
33李忠任.实验针灸学[M].第1版,北京：中国中医药出版社,2003：229-230.
34敖有光,杨运宽,胡幼平.针灸加穴位注射治疗痔瘘术后尿潴留67例[J].福建中医药,2003,34(6)：33.
35刘红,熊典樟,朱贤苟.针灸治疗182例药源性尿潴留的临床研究[J].中国民康医学杂志, 2003,15(9)：546.
36陈跃来,申鹏飞,陈国美,等.电针“会阳”、“中膂俞”对非细菌性前列腺炎大鼠尿流动力学影响的实验研究[J].针刺研究,2001,26(2)：127-130.
37王建文,赵耀东,雄成林.电针对大鼠前列腺增生的治疗作用及对一氧化氮内皮素的影响[J].中医药学刊,2004,22(11)：2130-2131.
38李锦宇,韩霞,汪晓斌.针灸免疫研究概况[J].动物医学进展,2008,29(11)：107-110.
39赵淑华,吉学群,许洪玲,等.血海穴活血化瘀功能的再评价[J].中国针灸,2004,24(7)：475-478.
40雷正权,殷克敬.针刺活血化瘀穴对血中纤维蛋白原的影响.陕西中医学院学报[J].1994,17(3)：15.
41朱静芬.针刺疗法与活血化瘀述略[J].中国中医药现代远程教育,2008,6(8)：932.
42徐天舒,针刺对老年眩晕症病人血液流变学的影响[J].针刺研究,2000,25(4)：281.
43王绍源,谭勇,黄静.川参通注射液治疗慢性前列腺炎[J].中华现代临床医学杂志,2004,2(7)：968.
44巫少荣,李白成,裘汉璋.当归在心血管系统的作用[J].中医药研究,2001,17(3)：56-58.
45韩联合,陈腾,冯国清.川芎嗪和透明质酸钠对兔心脏术后心包粘连的保护作用及对照研究[J].中国临床药理学与治疗学,2006,11(6)：665-668.
46杜健鹏,陈泽涛.益气活血法改善微循环的实验研究[J].中国实验方剂学杂志,2006,12(9)：31-35.
47刘艳凯,刘圣君,张玉平,等.川芎嗪、当归注射液对急性微循环障碍大鼠血小板功能和器官血流量的影响[J].中国医学物理学杂志,2005(5)：660-662.
48吴洪涛,刘紫庭,等.川参通对大鼠前列腺组织影响的实验研究[J].中国临床康复,2005,9(2)：190.
49邢子龙,许衍慧,解春洁.川参通治疗前列腺203例临床观察[J].现代中西医结合杂志,2005,14(1)：46.
50李文涛,宋荣坡,刘茂林.针药结合对脑缺血大鼠脑水肿防治作用的实验研究[J].陕西中医,2003,24(2)：178-179.
51王军,王玉升,齐小玲,等.针药合用对大鼠局灶性脑缺血预后的影响[J].中国临床康复,2002,6(13)：1914-1915.
52呙登俊,万同,田畯,等.尼莫地平联合电针治疗脑缺血再灌注损伤的机理[J].中国康复理论 与实践,2003,9(3)：141-143.
53刘丽军,杜惠兰,靳亚慈,等.针药结合对乳腺增生大鼠乳腺组织及雌激素受体亚型表达的影响[J].中国针灸,2007,27(4)：279-283.
1 Rowhrborm CG, McConnell JD. Etiology, pathothysiology, epidemiology and natural history of benign prostatic hyperplasia. In:Campbell's Urology. Edited by PC Walsh, AB Retik, ED Vaughan Jr and AJ Wein Philadelphia, PA:W.B. Saunders Company,2002,38:1297-1330.
2张祥华,王行环,王刚,等.良性前列腺增生诊断治疗指南[M].北京：人民卫生出版社,2007：146.
3鲍镇美.良性前列腺增生的药物治疗[J].中华泌尿外科杂志,1996,17：387.
4 Claus S,Berges R,Senge T,et al.Cell kinetic in epithelium and stro-ma of benign prostatic hyperplasia.J Utol,1997,158:217-21.
5 Sciarra F,Toscano V.Role of estrogens in human benign prostatic hyper-plasia.ArchAndrol, 2000,44(3),213-220.
6 Carballido,Rodriguez,Rodriguez Vallejo,et al.Benign prostatic hyperpla-sia and evidence based medicine:its approach in clinical practice. Med Clin(Barc),2000,114 Suppl 2,96-104.
7Furuya Y,et al.Endocrinology,1995,136:1898-1906.
8夏术阶,许纯孝,马庆铮等.前列腺阶段性增长的雄激素基础研究[J].中国男科学杂志,1999,13(4)：217-219.
9 Van-Coppenolle F,Slomianny C,Carpentier F,et al.Effects of hyperpro lactinemia on rat prostate growth:evidence of androgeno-dependence Am J Physiol Endocrinol,2001,280(1),120-29.
10 Hammarsten J,Hogstedt B.Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.Eur Urol,2001,39(2),151-158.
11 Mochtar CA,Rahardjo D,Umbas R.Ahigher PSA-density cut-off level inpatientswith intermediate PSA values for the early detection of prostate cancer.Gan To Kagaku Ryoho,2000, 27 Suppl 2,514-522.
12 Habermann Helga,Ray Vera,Habermann Walter,et al.Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol,2002,167(2 Pt 1), 655-660.
13 VictorVM,RochaM,DelaFuenteM.Immunecells:freeradicals and antioxidants in sepsis[J].Int Immunopharmacol,2004,4(3):327-347.
14 Kramer QMarberger M.Could inflammation be a key component in the progression of benign prostatic hyperplasia?[J].Curr Opin Urol,2006,16(1):25-29.
15 Penna G, Mondaini N, Amuchastegui S,et al. Seminal plasma andchemokinesin inflammatio cytokines prostate:interleukin 8 as a predictive biomarker in chronic prostat chronic pelvic pain syndrome and benign prostatic hyperplasia[J]. EurUrol,2007,51(2):524-533.
16 Aggarwal S,Gurney A L.IL-17:prototype member of an emerging cytokine family[J]. Leukocgte Biol,2002,71(1):1-8.
17 Konig J E,Senge T,Allhoff E P,et al.Analysis of the inflammatory network in benign prostate hyperplasia and prostatecancer[J].Prostate,2004,58(2):121-129.
18 Steiner G E,Stix U,Handisurya A,et al.Cytokine expres-cells and impact of lymphocytic infiltration on cytokine mRN A profile in prostatic tissue[J]. Lab Invest,2003,83(8):1131-1146.
19 Miller L J,Fischer K A,Goralnick S J,et al.Interleukin-10 levels in seminal plasma implicationsfor chronicpros tatitis chronicpelvicpainsyndrome[J].JUrol,2002,167(2Ptl): 753-756.
20 Jang T L,Schaefer A J.The role of cytokines in prostatisis[J].WorId J Urol2003,21(2):95-99.
21 Kramer Gero,Marberger Michae.1 Could inflammation be a key component in the progession of benign prostatic hyperplasia [J].CurrOpininUro,2006,16:25-29.
22 SteinerG, StixU, HandisuryaA, eta.l Cytokine expression pat-tern in benign prostatic hyperplasia infiltratingT cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue[J]. Lab Invest,2003,83:1131-1146.
23 KramerG, Mitteregger, MarbergerM. Is benign prostatic hyper-plasia (BPH) an immune inflammatory disease[J].EuropUrol,2007,51:1202-1216.
24陈和亮.实用中医男科临床手册[M].上海：上海中医药大学出版社,2006：159.
25郑中炎.中医基础理论体系现代研究[M].广东：广东科技出版社,2002：198.
26潘立群.试论前列腺增生症病机的确切含义[J].江苏中医药.2002,23(6)：1-2.
27何红兵.从瘀辨证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3)：181.